Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Kun-Sheng Lyu"'
Publikováno v:
Gastroenterology Report
Background Infliximab (IFX) is the first-line treatment for patients with Crohn’s disease (CD) and is noted for its relatively high cost. The therapeutic efficacy of IFX has noticeable individual differences. Known single-gene polymorphisms (SNPs)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2aedabba83207cf84dff718d840f56eb
https://doi.org/10.1093/gastro/goaa070
https://doi.org/10.1093/gastro/goaa070
Autor:
Min Huang, Xueding Wang, Xiang Gao, Zhongming Jin, Na You, Kun-Sheng Lyu, Caibin Zhang, Jian Tang, Shaoxing Guan
Publikováno v:
Gastroenterology Report. 8:367-373
Background Trough levels of the post-induction serum infliximab (IFX) are associated with short-term and long-term responses of Crohn’s disease patients to IFX, but the inter-individual differences are large. We aimed to elucidate whether single ge
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0d8f4dbb50f8788f77b93ff1684111a8
https://doi.org/10.1093/gastro/goz056
https://doi.org/10.1093/gastro/goz056